News
Get access to our breaking news, and company information
Press Releases
Pillar Biosciences Receives CMS Coverage for FDA Approved oncoReveal® CDx Pan-Cancer Solid tumor IVD Kit
April 3, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced they have received nationwide Medicare coverage by the Centers for Medicare
Pillar Biosciences and Hamilton Company Announce NGS Application Development and Co-Marketing Agreement
Collaboration aims to accelerate automation of rapid NGS testing February 18, 2025 – Pillar Biosciences, Inc., the leader in Decision Medicine™, has entered into a
Reflecting on 2024: A Year of Growth, Innovation, and Partnership at Pillar Biosciences
In 2024, Pillar Biosciences made significant strides in advancing our mission of Decision Medicine™ and improving cancer diagnostics through rapid, innovative Next-Generation Sequencing (NGS) kitted
Pillar Biosciences Enters into Strategic Licensing Agreement for MSK’s OncoKB™ Precision Medicine Knowledgebase
Agreement aims to enhance Pillar’s PiVat® bioinformatics platform with downstream reporting capabilities. NATICK, Mass – January 7, 2025 – Pillar Biosciences, Inc. has entered into
Cancer Centers Look to New NGS-Based ‘Frankenpanel’ to Get Fast Info on Clinically Actionable Genes
Originally posted on Genomeweb Premium by Andrew P. Han September 12, 2024 NEW YORK – Memorial Sloan Kettering Cancer Center (MSK) is in the process of implementing
Pillar Biosciences to Present Impactful Research Data at 2024 Association for Molecular Pathology (AMP) Annual Meeting
Natick, MA – November 14, 2024 – Pillar Biosciences, Inc., the leader in Decision Medicine™, announced its participation in the 2024 Association for Molecular Pathology (AMP) Annual Meeting